Geography, mobility and deprivation limit access to respiratory care.
Smartphone-based testing needs no extra hardware, bringing COPD and asthma monitoring within reach of more patients.
Wider access supports earlier detection and fairer care.
#COPD#Respiratory#DigitalHealth
Geography, mobility and deprivation limit access to respiratory care.
Smartphone-based testing needs no extra hardware, bringing COPD and asthma monitoring within reach of underserved patients.
Wider access supports earlier detection and fairer care.
#COPD#Asthma#Respiratory
Respiratory disease affects 500M+ people worldwide.
electronRx's white paper and clinical studies support continuous digital measurement across COPD, asthma, ILD and pulmonary hypertension
Continuous disease needs more than occasional care.
#Respiratory#Health#ChronicDisease
electronRx's continuous-monitoring work spans the UK and Japan, testing early detection of respiratory deterioration across different populations and care models.
For COPD, international evidence strengthens confidence in local clinical impact.
#COPD#Respiratory#DigitalHealth
Chronic disease drives most healthcare activity but care remains episodic.
Continuous heart and lung monitoring reveals changes between appointments, helping care teams deliver connected care.
Continuous insight supports clinical expertise.
#Respiratory#Health#DigitalHealth
COPD and asthma can deteriorate between appointments, where current models see least.
Continuous measurement gives an early deterioration signal to act on.
See the decline sooner, act sooner, and keep more patients out of hospital now.
#COPD#Asthma#Health#RemoteMonitoring
ILD monitoring relies on imaging, clinic visits, and symptoms, yet respiratory function can change quietly between assessments.
For ADCs, this creates a safety blind spot.
Continuous data can reveal changes.
New Blog π https://t.co/cI2Nju8Pvm
#ILD#DigitalHealth#Respiratory
electronRx pairs a smartphone-based measurement, returning respiratory results in sixty seconds
Applied across populations rather than a clinic, becoming a way to manage chronic disease burden at the level of health systems
https://t.co/PSWhtQP0Ei
#Health#Respiratory#MedTech
Weβre delighted to be attending ERS Congress 2026! πͺπΊ
Weβre looking forward to joining fellow professionals from across the respiratory community at ERS Congress 2026.
If youβre attending, weβd be delighted to connect and arrange a time to meet.
#ERS#Barcelona#Respiratory
Predicting and limiting treatment toxicity is becoming a key focus.
ILD shows the opportunity: identifying patients sooner and detecting early lung injury could enable precise decisions.
Safer treatment journeys define progress.
https://t.co/IqIENZKeij
#ADCs#ILD#Respiratory
Respiratory services are among the most pressured in the NHS.
Giving clinicians an early, objective read on which patients are deteriorating lets scarce capacity follow genuine risk rather than the calendar.
Read More π https://t.co/3JlhhHgyih
#COPD#Asthma#NHS
electronRxs respiratory measurement has been studied against clinical reference standards, with findings being prepared for peer-reviewed publications
Peer review is the discipline that separates a credible platform from a confident claim
https://t.co/ZvCOyvXaRl
#Respiratory
International evidence strengthens the case that early detection of deterioration travels, and that a smartphone-based platform can support exacerbation management wherever patients live.
https://t.co/rGJ0tAtev7
#COPD#Respiratory#Health
Adherence is where most monitoring quietly fails.
A sixty-second smartphone test that patients can do at home changes the adherence equation, and consistent measurement is what makes early detection of an exacerbation possible.
https://t.co/BKquHl8PDO
#Asthma#COPD
Smartphone measurements give that visibility without new hardware, turning the home into a monitored setting and a rising deterioration score into an early prompt to act.
Read Our New Blog π https://t.co/UsqVVyjeUM
#VirtualWards#RemoteMonitoring#DigitalHealth
In drug-induced ILD, the challenge is not awareness of the risk but visibility of what happens between assessments
Continuous respiratory measurement is designed to close that gap, observing change over time rather than an occasional scan
https://t.co/TFwwEIuefA
#ILD#Health
One platform, one smartphone, a widening clinical reach
electronRx captures biomechanical and physiological signals to return respiratory function in sixty seconds backed by 644 subjects across multiple investigations
https://t.co/Cb9swj4f8H
#DigitalHealth#Respiratory#Health
Claims are easy in digital health; evidence is harder.
electronRx's approach has been built on clinical investigation rather than assertion, with 644 subjects and a programme of further studies now underway across the UK and Japan.
#Respiratory#DigitalBiomarkers#Health
The cost of waiting is measured in both pounds and outcomes.
Continuous monitoring shifts the economics by catching deterioration early enough to manage it in the community rather than the acute ward.
Read Our New Blog π https://t.co/gwb6MPEitJ
#COPD#Asthma#Health
For clinicians and patients, tolerability matters just as much, because treatment-related toxicity drives dose reductions and hospitalisation.
ILD is among the most consequential of these risks, and its early signs are non-specific and easy to miss.
#ADCs#ILD#Health